Treatment for and Related Conditions Associated with Rhinitis, Asthma, Colds, Coughs

This review will highlight drugs in the cough/cold treatment area where the staff at IHC has had experience in designing, conducting, analyzing and reporting the clinical results. Taking just one company’s products for example – you can prepare to combat a competitor’s claims for Comtrex®, Theraflu®, even Buckley’s®, Delsym®, Otrivin® or pursue switching another of your competitor’s drugs in this arena from RxÞOTC (like Foradil®, Tobi® or Xolair®) – our staff at IHC has had direct, and recent, experience designing, conducting and analyzing clinical studies evaluating similar drugs. Our experience with drugs for allergic rhinitis, bronchospasms, asthma and related disorders including cold symptom/cough treatment enables us to quickly identify those clinical research centers that will meet the enrollment needs, even in the off-season.

SCOPE AND VARIABILITY OF EXPERTISE:

Through September, 2019, our staff has designed and conducted a wide range of studies evaluating over 7,100 subjects with rhinitis, asthma, coughs, colds and related conditions.

The studies, we designed and conducted, cover the full range of efficacy evaluations: single center methodology studies; chamber inhalation studies for pharmacodynamic/kinetic properties in normal as well as allergy distressed subjects; through “at-Home”, “In-Use” studies and sequestered studies to evaluate chronic cough treatments. We have seen what works, what truly doesn’t work, how best to squeeze more efficacy out of a clinical program, and how to identify ‘weakness’ in a clinical that may be seeking too many goals and miss the chance to tighten the study design, thereby secure the primary goals.

The Staff of IHC is ready and able to assist your company in securing the claims of your new drugs as well as defending and expanding the claims of your marketed drugs.